ZYXI - Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system
- Zynex ( NASDAQ: ZYXI ) announced it had begun enrollments to test its second generation monitoring system, CM-1600, in a large-scale blood loss detection trial.
- The multi-site trial, first initiated with ClinCept, is designed to determine the specificity and sensitivity of the CM-1600 in detecting minor blood loss during a whole blood donation procedure.
- The trial is expected to include up to 227 subjects and will complete enrollments in early 2023.
- ( ZYXI ) is trading ~2% higher.
For further details see:
Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system